Kolexia
Borel-Derlon Annie Médecine générale
Borel-Derlon Annie
Médecine générale
Hôpital Côte de Nacre
Caen, France
91 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Maladies de von Willebrand Hémorragie Hémophilie B Maladie de von Willebrand de type 2 Angiodysplasie Thrombose Syndromes lymphoprolifératifs Anévrysme

Collaborateurs

Voir plus
Repesse Yohann
Repesse Yohann
Hôpital Côte de Nacre, Caen, France
Goudemand Jenny
Goudemand Jenny
Institut Coeur Poumon Chu Lille, Lille, France
Harroche-Angel Annie
Harroche-Angel Annie
Hôpital Necker Enfants Malades, Paris, France
Susen Sophie
Susen Sophie
Centre de Biologie - Pathologie, Lille, France

Industries

Voir plus
Roche
21 collaboration(s)
Dernière en 2022
LFB
15 collaboration(s)
Dernière en 2023
Sobi
13 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
5 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Living with… hemophilia.
La Revue du praticien   29 février 2024
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD): A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Essai Clinique (Shire)   09 novembre 2023
Surgery in rare bleeding disorders: the prospective MARACHI study.
Research and practice in thrombosis and haemostasis   06 septembre 2023
Hémophilie
HAS Publications   20 juin 2023
Podcast Singularité S1E06 - Une maladie toujours mieux traitée : l'histoire du Dr Borel Derlon
Youtube @ Roche France   17 mars 2023
TRANSHEMO: Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   13 février 2023
PO221 TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
ELPOT: Evaluation of Perioperative Eltrombopag for the Management of Elective Surgery and Invasive Acts in Patients With Inherited Thrombocytopenia
Essai Clinique (CHU Toulouse)   02 janvier 2023
PO163 TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN ELDERLY PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting   31 janvier 2022
PO079 INNOVATIVE BREAKTHROUGH TREATMENT, THE FINANCING OF EDUCATIONAL PROGRAMMES IS THE RESPONSIBILITY OF MANUFACTURERS, A FIRST IN FRANCE WITH THE EXAMPLE OF EMICIZUMAB
15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting   31 janvier 2022